Everolimus vs Mycophenolate Mofetil in Heart TransplantationEverolimus vs Mycophenolate Mofetil in Heart Transplantation

In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil 3 g/day with standard-dose cyclosporine. American Journal of Transplantation
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news